ABUS Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -1463.52% compared to Arbutus Biopharma Corp.'s net margin of -255.85%. Arbutus Biopharma Corp.'s return on equity of -47.63% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Arbutus Biopharma Corp. has a consensus price target of $5.70, signalling upside risk potential of 19.18%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that Arbutus Biopharma Corp. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Arbutus Biopharma Corp. is more attractive than NovaBay Pharmaceuticals, Inc..

Arbutus Biopharma Corp. has a beta of 0.656, which suggesting that the stock is 34.407% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Arbutus Biopharma Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Arbutus Biopharma Corp. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Arbutus Biopharma Corp. quarterly revenues are $529K, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Arbutus Biopharma Corp.'s net income of -$7.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Arbutus Biopharma Corp.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arbutus Biopharma Corp. is 62.58x versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -1463.52% compared to Arbutus Biopharma Corp.'s net margin of --. Arbutus Biopharma Corp.'s return on equity of -47.63% beat Palatin Technologies's return on equity of --.

Arbutus Biopharma Corp. has a consensus price target of $5.70, signalling upside risk potential of 19.18%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Arbutus Biopharma Corp., analysts believe Palatin Technologies is more attractive than Arbutus Biopharma Corp..

Arbutus Biopharma Corp. has a beta of 0.656, which suggesting that the stock is 34.407% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Arbutus Biopharma Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arbutus Biopharma Corp. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Arbutus Biopharma Corp. quarterly revenues are $529K, which are larger than Palatin Technologies quarterly revenues of --. Arbutus Biopharma Corp.'s net income of -$7.7M is higher than Palatin Technologies's net income of --. Notably, Arbutus Biopharma Corp.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arbutus Biopharma Corp. is 62.58x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -1463.52% compared to Arbutus Biopharma Corp.'s net margin of --. Arbutus Biopharma Corp.'s return on equity of -47.63% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Arbutus Biopharma Corp. has a consensus price target of $5.70, signalling upside risk potential of 19.18%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3559.17%. Given that Theriva Biologics, Inc. has higher upside potential than Arbutus Biopharma Corp., analysts believe Theriva Biologics, Inc. is more attractive than Arbutus Biopharma Corp..

Arbutus Biopharma Corp. has a beta of 0.656, which suggesting that the stock is 34.407% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Arbutus Biopharma Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arbutus Biopharma Corp. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Arbutus Biopharma Corp. quarterly revenues are $529K, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Arbutus Biopharma Corp.'s net income of -$7.7M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Arbutus Biopharma Corp.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arbutus Biopharma Corp. is 62.58x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Trevi Therapeutics, Inc. has a net margin of -1463.52% compared to Arbutus Biopharma Corp.'s net margin of --. Arbutus Biopharma Corp.'s return on equity of -47.63% beat Trevi Therapeutics, Inc.'s return on equity of -35.48%.

Arbutus Biopharma Corp. has a consensus price target of $5.70, signalling upside risk potential of 19.18%. On the other hand Trevi Therapeutics, Inc. has an analysts' consensus of $21.30 which suggests that it could grow by 65.76%. Given that Trevi Therapeutics, Inc. has higher upside potential than Arbutus Biopharma Corp., analysts believe Trevi Therapeutics, Inc. is more attractive than Arbutus Biopharma Corp..

Arbutus Biopharma Corp. has a beta of 0.656, which suggesting that the stock is 34.407% less volatile than S&P 500. In comparison Trevi Therapeutics, Inc. has a beta of 0.825, suggesting its less volatile than the S&P 500 by 17.501%.

Arbutus Biopharma Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trevi Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arbutus Biopharma Corp. pays -- of its earnings as a dividend. Trevi Therapeutics, Inc. pays out -- of its earnings as a dividend.

Arbutus Biopharma Corp. quarterly revenues are $529K, which are larger than Trevi Therapeutics, Inc. quarterly revenues of --. Arbutus Biopharma Corp.'s net income of -$7.7M is higher than Trevi Therapeutics, Inc.'s net income of -$11.8M. Notably, Arbutus Biopharma Corp.'s price-to-earnings ratio is -- while Trevi Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arbutus Biopharma Corp. is 62.58x versus -- for Trevi Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.